APGE - Apogee Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$109.44
DETAILS
HIGH:
$140.00
LOW:
$83.00
MEDIAN:
$103.00
CONSENSUS:
$109.44
UPSIDE:
34.84%
About Apogee Therapeutics, Inc. (https://www.apogeetherapeutics.com)
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Michael Thomas Henderson | Chief Executive Officer & Director | 1990 | $1,291,500 USD |
| Carl Linden Dambkowski | Chief Medical Officer | 1985 | $855,900 USD |
| Jane Pritchett V. Henderson | Chief Financial Officer | 1966 | $855,900 USD |
| Drew Badger | Senior Vice President and Head of Regulatory Affairs & Toxicology | – | – |
| Emily Cox | SVP & Head of People | – | – |
| Matthew Batters | Chief Legal Officer & Corporate Secretary | 1976 | – |
| Monica Forbes | Senior Vice President of Finance | 1976 | – |
| Noel Kurdi | Vice President of Investor Relations | – | – |
| Rebecca Dabora | Chief Development Officer | 1959 | – |
| Wendy Aspden-Curran | Senior Vice President of Clinical Operations | – | – |